Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of pharmacological sciences"
DOI: 10.1016/j.jphs.2021.03.001
Abstract: We performed clinical retrospective study in female cancer patients and fundamental experiments in mice, in order to clarify risk factors for paclitaxel-induced peripheral neuropathy (PIPN). In the clinical study, 131 of 189 female outpatients with… read more here.
Keywords: paclitaxel induced; peripheral neuropathy; study; induced peripheral ... See more keywords
Shaoyao Gancao Decoction Ameliorates Paclitaxel-Induced Peripheral Neuropathy via Suppressing TRPV1 and TLR4 Signaling Expression in Rats
Sign Up to like & getrecommendations! Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s357638
Abstract: Purpose Paclitaxel-induced peripheral neuropathy (PIPN) is increasingly becoming one of the most widespread adverse effects in the treatment of cancer patients, and further precipitate neuroinflammation in the nervous system. Interestingly, Shaoyao Gancao Decoction (SGD), a… read more here.
Keywords: pipn; peripheral neuropathy; expression; tlr4 ... See more keywords